REPLY
28.1.2021 09:32:11 CET | Business Wire | Press release
Reply announced today that its companies Storm Reply and Spike Reply achieved Amazon Web Services (AWS) Security Competency status. This designation recognizes that the two companies of the Reply Group have demonstrated deep expertise that helps customers achieve their cloud security goals.
Achieving the AWS Security Competency differentiates Storm Reply and Spike Reply as AWS Partner Network (APN) members that provide specialized consultancy services and integrated solutions designed to help enterprises adopt, develop and deploy complex security projects on AWS. To receive the designation, APN Partners must possess deep AWS expertise and deliver solutions seamlessly on AWS.
Filippo Rizzante, CTO Reply, commented: “We are proud to be among the first APN partners to achieve AWS Security Competency status. This AWS competency status confirms the ability of our teams in helping companies achieve their security goals by combining our expertise with the range of powerful security tools that AWS provides”.
Respectively, Storm Reply and Spike Reply have a deep expertise in supporting companies worldwide in the implementation of Cloud-based systems and applications and in the deployment of integrated solutions for business security.
AWS is enabling scalable, flexible, and cost-effective solutions from start-ups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise.
As APN Premier Consulting Partner, Reply helps customers wishing to enhance their security posture by leveraging on cloud-based solutions and services that allow to develop effective cyber risk management programs.
Spike Reply
Spike Reply specialises on Cyber Security, Personal Data protection and tailored Managed Security Services. Spike Reply Cyber Security services range from helping customer to develop an effective cyber risk management program, in line with the strategic objectives and risk appetite of the organization, to the planning, design and implementation of all the corresponding technological, legal, organizational, underwriting and risk-limiting countermeasures. With a broad network of partnerships, Spike Reply select the most appropriate security solutions and helps organizations to improve their cyber response capabilities through its advanced threat simulation. www.reply.com
Storm Reply
Storm Reply is the Reply Group Company specializing in design and implementation of cloud-based solutions and services. Storm Reply holds Amazon Premier Consulting Partner Status since 2014 and helped a large number of relevant customers in Europe to run their systems and applications on the AWS Platform. Having a consolidated experience in Cloud IaaS, PaaS and SaaS architectures, Storm Reply provides an end to end set of services for Cloud Adoption, Development of new applications and management full services of their cloud environment. Having deep competencies and experiences on management of complex cloud projects, Storm Reply helps customers to implement their Strategy Cloud Approach. In particular, Storm Reply offers services on Cloud Strategy and Migration, Cloud Native Applications development and Cloud Service Management. www.storm.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom